Literature DB >> 32658129

Comparison of [11C]-PBR28 Binding Between Persons Living With HIV and HIV-Uninfected Individuals.

Anna H Boerwinkle1, Jeremy F Strain1, Tricia Burdo2, John Doyle1, Jon Christensen3, Yi Su4, Julie K Wisch1, Sarah A Cooley1, Florin Vaida5, Mandy D Smith2, Hussain Jafri3, Robert H Paul6, Tammie L S Benzinger3, Beau M Ances1,3,7.   

Abstract

OBJECTIVE: Despite combined antiretroviral therapy, neuroinflammation may persist in persons living with HIV (PLWH) and contribute to cognitive impairment in this population. Positron emission tomography (PET) imaging targeting 18 kDa translocator protein (TSPO) has been used to localize neuroinflammation. We aimed to use TSPO-PET imaging to evaluate neuroinflammation in PLWH.
DESIGN: Twenty-four virologically suppressed PLWH on combined antiretroviral therapy and 13 HIV-negative (HIV-) controls completed TSPO-PET imaging using the radiotracer [C]PBR28. Because of tracer complexity and differing procedures used in previous studies, we employed an expansive methodological approach, using binding potential (BP) and standard uptake value ratio and multiple different reference regions to estimate [C]PBR28 binding.
METHODS: [C]PBR28 binding was measured in 30 cortical and subcortical regions and compared between PLWH and HIV- controls. Pearson correlation evaluated the association between [C]PBR28 binding and cognition and clinical measures of HIV.
RESULTS: Analyses conducted using multiple reference regions and measures of tracer uptake revealed no significant differences between [C]PBR28 binding in PLWH compared with HIV- controls. In addition, [C]PBR28 binding in PLWH was not significantly associated with clinical measures of HIV or plasma biomarkers of inflammation. [C]PBR28 binding was not significantly elevated in cognitively impaired PLWH compared with unimpaired PLWH, but there were inverse relationships between cognitive performance (executive and global function) and [C]PBR28 binding in PLWH.
CONCLUSIONS: Our results suggest that neuroinflammation may play a role in cognitive deficits, but overall neuroinflammatory levels as measured by TSPO-PET imaging in PLWH are not significantly different from those seen in HIV- controls.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32658129      PMCID: PMC8053041          DOI: 10.1097/QAI.0000000000002435

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN: 1525-4135            Impact factor:   3.771


  40 in total

Review 1.  Molecular Imaging of Neuroinflammation in HIV.

Authors:  Anna Boerwinkle; Beau M Ances
Journal:  J Neuroimmune Pharmacol       Date:  2018-12-05       Impact factor: 4.147

Review 2.  Neuroimaging of HIV-associated neurocognitive disorders (HAND).

Authors:  Beau M Ances; Dima A Hammoud
Journal:  Curr Opin HIV AIDS       Date:  2014-11       Impact factor: 4.283

Review 3.  Reconceptualization of translocator protein as a biomarker of neuroinflammation in psychiatry.

Authors:  T Notter; J M Coughlin; A Sawa; U Meyer
Journal:  Mol Psychiatry       Date:  2017-12-05       Impact factor: 15.992

Review 4.  HIV-associated neurocognitive disorder.

Authors:  David B Clifford
Journal:  Curr Opin Infect Dis       Date:  2017-02       Impact factor: 4.915

5.  Central nervous system viral invasion and inflammation during acute HIV infection.

Authors:  Victor Valcour; Thep Chalermchai; Napapon Sailasuta; Mary Marovich; Sukalaya Lerdlum; Duanghathai Suttichom; Nijasri C Suwanwela; Linda Jagodzinski; Nelson Michael; Serena Spudich; Frits van Griensven; Mark de Souza; Jerome Kim; Jintanat Ananworanich
Journal:  J Infect Dis       Date:  2012-05-02       Impact factor: 5.226

6.  Antiretroviral treatment effect on immune activation reduces cerebrospinal fluid HIV-1 infection.

Authors:  Elizabeth Sinclair; Rollie Ronquillo; Nicole Lollo; Steven G Deeks; Peter Hunt; Constantin T Yiannoutsos; Serena Spudich; Richard W Price
Journal:  J Acquir Immune Defic Syndr       Date:  2008-04-15       Impact factor: 3.731

7.  Monocyte activation markers in cerebrospinal fluid associated with impaired neurocognitive testing in advanced HIV infection.

Authors:  Anupa Kamat; Jennifer L Lyons; Vikas Misra; Hajime Uno; Susan Morgello; Elyse J Singer; Dana Gabuzda
Journal:  J Acquir Immune Defic Syndr       Date:  2012-07-01       Impact factor: 3.731

8.  Increased microglia activation in neurologically asymptomatic HIV-infected patients receiving effective ART.

Authors:  Lucy J Garvey; Nicola Pavese; Marios Politis; Anil Ramlackhansingh; David J Brooks; Simon D Taylor-Robinson; Alan Winston
Journal:  AIDS       Date:  2014-01-02       Impact factor: 4.177

Review 9.  PET Imaging of Microglial Activation-Beyond Targeting TSPO.

Authors:  Bieneke Janssen; Danielle J Vugts; Albert D Windhorst; Robert H Mach
Journal:  Molecules       Date:  2018-03-08       Impact factor: 4.411

10.  Determination of [(11)C]PBR28 binding potential in vivo: a first human TSPO blocking study.

Authors:  David R Owen; Qi Guo; Nicola J Kalk; Alessandro Colasanti; Dimitra Kalogiannopoulou; Rahul Dimber; Yvonne L Lewis; Vincenzo Libri; Julien Barletta; Joaquim Ramada-Magalhaes; Aruloly Kamalakaran; David J Nutt; Jan Passchier; Paul M Matthews; Roger N Gunn; Eugenii A Rabiner
Journal:  J Cereb Blood Flow Metab       Date:  2014-03-19       Impact factor: 6.200

View more
  3 in total

Review 1.  Neuroimaging the Neuropathogenesis of HIV.

Authors:  Anna H Boerwinkle; Karin L Meeker; Patrick Luckett; Beau M Ances
Journal:  Curr HIV/AIDS Rep       Date:  2021-02-25       Impact factor: 5.071

Review 2.  Novel PET Imaging of Inflammatory Targets and Cells for the Diagnosis and Monitoring of Giant Cell Arteritis and Polymyalgia Rheumatica.

Authors:  Kornelis S M van der Geest; Maria Sandovici; Pieter H Nienhuis; Riemer H J A Slart; Peter Heeringa; Elisabeth Brouwer; William F Jiemy
Journal:  Front Med (Lausanne)       Date:  2022-06-06

Review 3.  Have (R)-[11C]PK11195 challengers fulfilled the promise? A scoping review of clinical TSPO PET studies.

Authors:  Fabien Chauveau; Guillaume Becker; Hervé Boutin
Journal:  Eur J Nucl Med Mol Imaging       Date:  2021-08-13       Impact factor: 9.236

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.